12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TH-302: Phase III amended

Threshold said FDA approved 2 amendments to its open-label, international Phase III trial comparing 300 mg/m 2 TH-302 on days 1 and 8 of a 21-day cycle plus doxorubicin vs. doxorubicin alone in patients with unresectable STS who have not previously received chemotherapy outside the adjuvant or neoadjuvant setting. Threshold amended the trial to increase enrollment to 620 patients from 450 and remove...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >